Updated November 12, 2026: After publication, Neurosterix identified the investors in its Series B financing. RTW Investments led the round; new investors included Janus Henderson Investors, Google Ventures (GV), Ikarian Capital, Affinity Asset Advisors and Dellora Investments, while Series A investors Perceptive Advisors and Acorn Bioventures also participated.
In November 2024, AbbVie’s emraclidine, a drug designed to treat schizophrenia by amplifying the brain’s M4 muscarinic receptor, missed the primary endpoint in both of its Phase 2 trials. Two years on, M4 drugs are still in development at AbbVie and at least three other companies.
On November 11, Neurosterix, a private company spun out of Addex Therapeutics in 2024, closed a $105 million Series B, mainly to take its own M4 drug, NTX-253, into Phase 2. AbbVie itself has been running a new emraclidine trial since August 2025. The money does not show that NTX-253 works. It does show that investors were willing to fund another M4 PAM into Phase 2 after emraclidine’s failure.
What emraclidine’s failure did and did not show
Emraclidine is a positive allosteric modulator, or PAM: it does not switch the M4 receptor on by itself but strengthens the response to the brain’s own acetylcholine. In EMPOWER-1 and EMPOWER-2, each with about 375 patients in an acute episode, no dose separated from placebo on the Positive and Negative Syndrome Scale (PANSS), the standard symptom score, at week 6:
| Trial | Placebo | Lower dose | 30 mg |
|---|---|---|---|
| EMPOWER-1 | −13.5 | −14.7 (10 mg) | −16.5 |
| EMPOWER-2 | −16.1 | −18.5 (15 mg) | −14.2 |
Change from baseline in PANSS total score at week 6, per AbbVie’s November 11, 2024 release.
The drug-arm improvements were within about three points of placebo, and in EMPOWER-2 the higher dose did worse than the lower one. Placebo arms improved by 13.5 and 16.1 points. The public data cannot say whether the drug’s mechanism, its exposure at these doses, or the trials’ placebo response was the main problem. AbbVie said at the time it was continuing to analyze the data. In its 2024 annual report it wrote emraclidine’s value down from $6.9 billion to $2.4 billion, a $4.5 billion pre-tax charge, and kept the remainder on its books.
Its next step has been on the registry since last year. A 268-patient Phase 2 that began in August 2025 tests emraclidine first in multiple ascending doses for up to 21 days, measuring blood levels of the drug and a metabolite, then in a 6-week placebo-controlled efficacy part. A design that starts by escalating dose and measuring exposure is consistent with a question about how much drug the earlier trials delivered, though AbbVie has not said that is its hypothesis. Primary completion is estimated for February 2028.
The rest of the M4 field
The receptor itself has positive evidence behind it, though not for PAMs:
- Bristol Myers Squibb’s Cobenfy (xanomeline and trospium), approved in 2024, activates both M1 and M4 receptors. Its approval does not separate the contribution of each.
- Neurocrine’s direclidine (NBI-1117568) activates M4 directly at the receptor’s main binding site, unlike a PAM. In a 210-patient Phase 2 it beat placebo by 7.5 PANSS points at 20 mg once daily (effect size 0.61), while the three higher regimens (40 mg and 60 mg once daily, and 30 mg twice daily) did not reach significance. A Phase 3 began in May 2025, with primary completion estimated for October 2027.
- Neurocrine’s NBI-1117570, a second muscarinic candidate, began a 120-patient Phase 2 in February 2026.
- Neumora named NMRA-898, an M4 PAM in Phase 1, the lead of its M4 franchise in March 2026, citing a human half-life of about 80 to 100 hours. Its August 14 update still guided to Phase 1 data in the second half of 2026.
So the selective M4 record is one positive Phase 2 for a direct agonist, at its lowest dose, and two negative Phase 2s for a PAM. The other M4 PAMs named here have not reported efficacy data.
What the $105 million is buying
Neurosterix’s own disclosures are thin. Most of what is public comes from Addex announcements:
- NTX-253’s Phase 1 combined single and multiple ascending doses in healthy volunteers and stable schizophrenia patients, with food-effect and cerebrospinal fluid measurements, and “provided important safety and pharmacokinetic data.” No doses, exposures, adverse-event rates or CSF results have been released. The registry record, last updated January 15, 2026, lists an estimated 73 participants and still shows the trial as recruiting.
- On November 12, a PubMed search found four Neurosterix-affiliated papers, on programs other than NTX-253, and a web search found no NTX-253 conference presentation. How its selectivity, potency or brain penetration compares with emraclidine’s cannot be assessed from public information.
- The financing announcement described the Series B investors only as “a syndicate of leading life science investors.” Neurosterix subsequently told Behavioral Wire that RTW Investments led the round; that Janus Henderson Investors, Google Ventures (GV), Ikarian Capital, Affinity Asset Advisors and Dellora Investments joined as new investors; and that Series A investors Perceptive Advisors and Acorn Bioventures also participated. Individual investment amounts have not been disclosed. The Series A in 2024 was led by funds affiliated with Perceptive Advisors, with Acorn Bioventures.
- The Phase 2 design, size and timing have not been disclosed, and no Phase 2 appears on ClinicalTrials.gov as of November 12.
Asked about the Phase 1 results, planned Phase 2 design, pharmacological differences from emraclidine and the Series B investors, Neurosterix initially referred Behavioral Wire to its public financing announcement. After publication it identified the Series B investors. It has not provided additional information on the Phase 1 results, the planned Phase 2 design, how NTX-253 differs pharmacologically from emraclidine, or its interpretation of emraclidine’s failures.
The CSF measurements matter. Whether an M4 drug reaches the brain at useful levels is one of the questions a Phase 1 can begin to answer, and Neumora’s NMRA-898 Phase 1 is designed to confirm CNS penetration through CSF exposure. Neurosterix has not said what its CSF data showed.
Addex accounts for its stake by the equity method, and its share of Neurosterix’s losses implies the company lost about CHF 43 million from its April 2024 launch through June 2026, roughly $51 million at the European Central Bank’s average franc-dollar rate over the period. The Series A was $63 million to $65 million (Behavioral Wire arithmetic; losses are not the same as cash spent).
An ownership figure that does not add up simply
Addex said on October 8 that it held 20 percent of Neurosterix. After the Series B, in which it did not invest, it reports 8.5 percent, valued at $18.6 million. That valuation implies about $219 million for the whole company. But if $219 million were the post-money value, with the round simply $105 million of new shares, a 20 percent holder would fall to about 10 percent, not 8.5 (Behavioral Wire arithmetic). The gap could reflect a larger option pool, converted notes, a different share class or a valuation method that does not price Addex’s units at the Series B price. Addex has not explained it, and the $219 million figure should not be read as a post-money valuation until it does.
What the round establishes is narrower than its size suggests. A syndicate led by RTW Investments was willing to fund the next test of an M4 PAM. That is a decision about one molecule’s next trial. The question emraclidine left open, whether amplifying M4 can treat schizophrenia at all, will be answered in controlled trials that have not finished: AbbVie’s restarted study, with an estimated primary completion of February 2028; Neurosterix’s planned Phase 2, which has no registry record yet; and, eventually, Neumora’s programs. Neurocrine’s Phase 3, of a drug that works differently, is estimated to finish in October 2027.